Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke (LUNASTROKE)

Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke, Experimental Study in Single Cases.

Recent work on large cohorts of chronic stroke (>6 months post-stroke) have shown that intensive training of the upper limb in the chronic stroke patients can lead to substantial motor and functional gains that are maintained at 6 months post intervention.

A very prolonged (12 weeks) and very intensive (5 hours daily) training applied to chronic patients after stroke brings a substantial gain both motor and functional which is maintained at 3 months post intervention.

Robotic rehabilitation have been shown to be as effective as any other treatment used in rehabilitation. But the methods of implementation remain widely debated. At that time, most robotic therapies have tried to reproduce functional movement mainly pointing objects.

We want to demonstrate that analytic movements of the elbow and the shoulder performed with the Luna-EMG robot can replace part of usual physiotherapy treatment with at least the same effectiveness on the recovery of fluid movements of the upper limb after a stroke.

Study Overview

• Status: Recruiting
• Conditions: Stroke
• Intervention / Treatment: Device: LUNA-EMG Robot

Detailed Description

This is a pilot study following a single case experimental design with multiple baselines across subjects (MBD).

People included in the protocol will benefit from 2 hours of daily treatment during 6 to 7.5 weeks. The first 2 weeks will be dedicated to baseline measurement of their upper limb (UL) status with daily treatment for balance and gait control without any treatment of the upper limb. The rest of the time will be dedicated to upper limb treatment exclusively. It will be divided into 2 UL training periods, one of them including a 30mn treatment with the luna EMG robot. The duration of second period will be randomly defined between 2 to 3.5 weeks and the last period will last 2 weeks. The treatment during the first UL treatment period will be randomly allocated to Luna EMG treatment or not. The next period will thus follow the inverse scheme (without if the first contains Luna EMG treatment). The fluidity will be assessed through pointing movements assessed every two days. Evaluation of motor deficiency (Fugl Meyer) and functional status (ARAT score) of the UL will be weekly assessed after the inclusion visit. 3D motion analysis of the UL will also be weekly performed.

All patients will benefit from a regular follow-up and from an organized care protocol. The sessions will be intensive, all subjects will be able to benefit from the new treatment (LUNA EMG). We can expect a direct individual benefit from the proposed intensive treatment, at least for precision of UL movements.

• Study Type: Interventional
• Enrollment (Estimated): 5
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Olivier Remy-Neris, PU-PH; Phone Number: +33 2 98 22 31 52; Email: olivier.remyneris@chu-brest.fr
• Study Contact Backup: Name: Gwenaël Cornec, MD; Email: gwenael.cornec@chu-brest.fr

Study Locations

• France
  • Brest, France, 29200
    • Recruiting
    • Chu Brest
    • Contact: Olivier Remy-Neris, PU-PH; Phone Number: +332 98 22 31 52; Email: olivier.remyneris@chu-brest.fr
    • Principal Investigator: Olivier Remy-Neris, PU-PH

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age >= 18 years
• Hemiparesis after a first stroke with more than 1 year time interval
• Functional upper limb: ability to do a pointing task at 90% of the hand-acromion distance (free trunk).
• Spastic hypertonia of the elbow flexors 0-2/4 on the Modified Ashworth scale
• Patient affiliated with social security
• Patient having signed a consent to participate in the research

Exclusion Criteria:

• Inability to sign written consent
• Flexed elbow > 30° during passive mobilization of the upper limb
• EVA>3 in the upper limb at rest or during mobilization
• Complete loss of upper limb proprioception
• Neuro-orthopedic surgery of the upper limb for spasticity: neurotomy, tenotomy, transfer
• Pregnant or breastfeeding woman

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Experimental Scheme : A,B,C; The phase B treatment (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot) is scheduled before phase C (2 hours a day, 5/7 days of conventional rehabilitation). The duration of phase B is randomized between 6 and 11 evaluations (2 to 3.5 weeks).	Device: LUNA-EMG Robot; During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.
Active Comparator: Experimental Scheme : A,C,B; The phase C treatment (2 hours a day, 5/7 days of conventional rehabilitation) is scheduled before phase B (1.5 hours a day, 5/7 days of conventional rehabilitation and 30mn a day, 5/7 days of treatment with the robot). The duration of phase C is randomized between 6 and 11 evaluations (2 to 3.5 weeks).	Device: LUNA-EMG Robot; During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Fluidity of the upper limb	Repeated evaluation of hand movement by the SPARC index during five pointing tasks at 90% of the length of the upper limb at clavicle height, at comfortable speed.	up to 7.5weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain assessment	Use of Visual Analog Scale (VAS) to evaluate the painful (between 0: no pain to 10: intolerable pain)	up to 7.5weeks
Motricity assessment	Use of the Fugl-Meyer index (between 0: no motricity to 66: total member motricity)	up to 7.5weeks
Function assessment	ARAT (Action Research Arm Test) measurement to assess specific changes in limb function (from 0 to 57, a low score indicating that the movements cannot be performed, and a high score indicating normal performance)	up to 7.5weeks
Duration of movement	Kinematic parameter measured 3 times per week	up to 7.5weeks
Straightness of movement	Kinematic parameter measured 3 times per week : the trajectory of the hand during pointing movement at a distance normalised by the length of the upper limb will be assessed in motion capture (12 VICONR cameras). The smoothness of the trajectory will be measured by the SPARC (spectral arc length measure) during forward and backward movement.	up to 7.5weeks
Average speed of movement	Kinematic parameter measured 3 times per week : the trajectory of the hand during pointing movement at a distance normalised by the length of the upper limb will be assessed in motion capture (12 VICONR cameras). The spatiotemporal parameters (time, distance, average speed) will be measured between the starting position (in front of the trunc) and the final pointed object during forward and backward movement.	up to 7.5weeks
Acceptability of the use of the robot	Score between 0 to 100 (a low score indicate that the robot is not well accepted, and a high score indicate a well acceptability)	up to 7.5weeks
Satisfaction of the use of the robot	Score between 0 to 100 (0: not satisfied, 100: very satisfied)	up to 7.5weeks
Spasticity	Ashworth scale measured 3 times a week and Nottingham scale measured 1 time at inclusion)	up to 7.5weeks

Collaborators and Investigators

• Sponsor: University Hospital, Brest
• Collaborators: EGZOTech
• Investigators: Principal Investigator: Olivier Remy-Neris, PU-PH, CHRU BREST

Study record dates

Study Major Dates

• Study Start (Actual): June 12, 2023
• Primary Completion (Estimated): June 12, 2026
• Study Completion (Estimated): June 12, 2026

Study Registration Dates

• First Submitted: March 9, 2022
• First Submitted That Met QC Criteria: June 5, 2023
• First Posted (Actual): June 15, 2023

Study Record Updates

• Last Update Posted (Actual): June 24, 2025
• Last Update Submitted That Met QC Criteria: June 23, 2025
• Last Verified: June 1, 2025

More Information

Terms related to this study

• Keywords: Robot; Joint
• Additional Relevant MeSH Terms: Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases; Stroke
• Other Study ID Numbers: 29BRC21.0393; 2022-A00096-37 (Other Identifier: Agence nationale de sécurité du médicament et des produits de santé)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: All collected data that underlie results in a publication
• IPD Sharing Time Frame: Data will be available beginning five years and ending fifteen years following the final study report completion
• IPD Sharing Access Criteria: Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No